Filtered By:
Cancer: Gastric (Stomach) Cancer
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 20058 results found since Jan 2013.
The Role of Tumor-related LncRNA PART1 in cancer
CONCLUSION: PART1 is closely related to tumors by regulating a variety of molecular mechanisms. In addition, PART1 can be used as a clinical marker for the early diagnosis of tumors and plays an important role in tumor-targeted therapy.PMID:34225608 | DOI:10.2174/1381612827666210705161955
Source: Current Pharmaceutical Design - July 6, 2021 Category: Drugs & Pharmacology Authors: Jinlan Chen Enqing Meng Yexiang Lin Yujie Shen Chengyu Hu Gang Zhou Chengfu Yuan Source Type: research
Artificial intelligence technologies empowering identification of novel diagnostic molecular markers in gastric cancer
Indian J Pathol Microbiol. 2021 Jun;64(Supplement):S63-S68. doi: 10.4103/IJPM.IJPM_950_20.ABSTRACTIn recent clinical practice the molecular diagnostics have been significantly empowered and upgraded by the use of Artificial Intelligence and its assisted technologies. The use of Machine leaning and Deep Learning Neural network architectures have brought in a new dimension in clinical oncological research and development. These algorithm based software system with enhanced digital image analysis have emerged into a new branch of digital pathology and contributed immensely towards precision medicine and personal diagnostics. ...
Source: Indian Journal of Pathology and Microbiology - June 17, 2021 Category: Pathology Authors: Ishan Pandey Vatsala Misra Aprajita T Pandey Pramod W Ramteke Ranjan Agrawal Source Type: research
The Role of Tumor-related LncRNA PART1 in cancer
CONCLUSION: PART1 is closely related to tumors by regulating a variety of molecular mechanisms. In addition, PART1 can be used as a clinical marker for the early diagnosis of tumors and plays an important role in tumor-targeted therapy.PMID:34225608 | DOI:10.2174/1381612827666210705161955
Source: Current Pharmaceutical Design - July 6, 2021 Category: Drugs & Pharmacology Authors: Jinlan Chen Enqing Meng Yexiang Lin Yujie Shen Chengyu Hu Gang Zhou Chengfu Yuan Source Type: research
Artificial intelligence technologies empowering identification of novel diagnostic molecular markers in gastric cancer
Indian J Pathol Microbiol. 2021 Jun;64(Supplement):S63-S68. doi: 10.4103/IJPM.IJPM_950_20.ABSTRACTIn recent clinical practice the molecular diagnostics have been significantly empowered and upgraded by the use of Artificial Intelligence and its assisted technologies. The use of Machine leaning and Deep Learning Neural network architectures have brought in a new dimension in clinical oncological research and development. These algorithm based software system with enhanced digital image analysis have emerged into a new branch of digital pathology and contributed immensely towards precision medicine and personal diagnostics. ...
Source: Indian Journal of Pathology and Microbiology - June 17, 2021 Category: Pathology Authors: Ishan Pandey Vatsala Misra Aprajita T Pandey Pramod W Ramteke Ranjan Agrawal Source Type: research
The Role of Tumor-related LncRNA PART1 in cancer
CONCLUSION: PART1 is closely related to tumors by regulating a variety of molecular mechanisms. In addition, PART1 can be used as a clinical marker for the early diagnosis of tumors and plays an important role in tumor-targeted therapy.PMID:34225608 | DOI:10.2174/1381612827666210705161955
Source: Current Pharmaceutical Design - July 6, 2021 Category: Drugs & Pharmacology Authors: Jinlan Chen Enqing Meng Yexiang Lin Yujie Shen Chengyu Hu Gang Zhou Chengfu Yuan Source Type: research
Artificial intelligence technologies empowering identification of novel diagnostic molecular markers in gastric cancer
Indian J Pathol Microbiol. 2021 Jun;64(Supplement):S63-S68. doi: 10.4103/IJPM.IJPM_950_20.ABSTRACTIn recent clinical practice the molecular diagnostics have been significantly empowered and upgraded by the use of Artificial Intelligence and its assisted technologies. The use of Machine leaning and Deep Learning Neural network architectures have brought in a new dimension in clinical oncological research and development. These algorithm based software system with enhanced digital image analysis have emerged into a new branch of digital pathology and contributed immensely towards precision medicine and personal diagnostics. ...
Source: Indian Journal of Pathology and Microbiology - June 17, 2021 Category: Pathology Authors: Ishan Pandey Vatsala Misra Aprajita T Pandey Pramod W Ramteke Ranjan Agrawal Source Type: research
The Role of Tumor-related LncRNA PART1 in cancer
CONCLUSION: PART1 is closely related to tumors by regulating a variety of molecular mechanisms. In addition, PART1 can be used as a clinical marker for the early diagnosis of tumors and plays an important role in tumor-targeted therapy.PMID:34225608 | DOI:10.2174/1381612827666210705161955
Source: Current Pharmaceutical Design - July 6, 2021 Category: Drugs & Pharmacology Authors: Jinlan Chen Enqing Meng Yexiang Lin Yujie Shen Chengyu Hu Gang Zhou Chengfu Yuan Source Type: research
Artificial intelligence technologies empowering identification of novel diagnostic molecular markers in gastric cancer
Indian J Pathol Microbiol. 2021 Jun;64(Supplement):S63-S68. doi: 10.4103/IJPM.IJPM_950_20.ABSTRACTIn recent clinical practice the molecular diagnostics have been significantly empowered and upgraded by the use of Artificial Intelligence and its assisted technologies. The use of Machine leaning and Deep Learning Neural network architectures have brought in a new dimension in clinical oncological research and development. These algorithm based software system with enhanced digital image analysis have emerged into a new branch of digital pathology and contributed immensely towards precision medicine and personal diagnostics. ...
Source: Indian Journal of Pathology and Microbiology - June 17, 2021 Category: Pathology Authors: Ishan Pandey Vatsala Misra Aprajita T Pandey Pramod W Ramteke Ranjan Agrawal Source Type: research
The Role of Tumor-related LncRNA PART1 in cancer
CONCLUSION: PART1 is closely related to tumors by regulating a variety of molecular mechanisms. In addition, PART1 can be used as a clinical marker for the early diagnosis of tumors and plays an important role in tumor-targeted therapy.PMID:34225608 | DOI:10.2174/1381612827666210705161955
Source: Current Pharmaceutical Design - July 6, 2021 Category: Drugs & Pharmacology Authors: Jinlan Chen Enqing Meng Yexiang Lin Yujie Shen Chengyu Hu Gang Zhou Chengfu Yuan Source Type: research
Artificial intelligence technologies empowering identification of novel diagnostic molecular markers in gastric cancer
Indian J Pathol Microbiol. 2021 Jun;64(Supplement):S63-S68. doi: 10.4103/IJPM.IJPM_950_20.ABSTRACTIn recent clinical practice the molecular diagnostics have been significantly empowered and upgraded by the use of Artificial Intelligence and its assisted technologies. The use of Machine leaning and Deep Learning Neural network architectures have brought in a new dimension in clinical oncological research and development. These algorithm based software system with enhanced digital image analysis have emerged into a new branch of digital pathology and contributed immensely towards precision medicine and personal diagnostics. ...
Source: Indian Journal of Pathology and Microbiology - June 17, 2021 Category: Pathology Authors: Ishan Pandey Vatsala Misra Aprajita T Pandey Pramod W Ramteke Ranjan Agrawal Source Type: research
Towards a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
CONCLUSION: For advanced G/GEA, review of trial results from 2009-2019 support 1L therapy with platinum and fluoropyrimidine and sequencing with taxanes or irinotecan in combination with biologics as effective 2L options. Escalating to a triplet may add some efficacy at the expense of added toxicity.IMPLICATIONS FOR PRACTICE: The rapidly changing treatment landscape for advanced gastric cancer includes increasing options for refractory disease. With multiple first-line platinum-based regimens, identification of those with the best benefit-to-risk ratio may provide guidance on treatment sequencing strategies. Herein, we pre...
Source: The Oncologist - July 21, 2021 Category: Cancer & Oncology Authors: Daniel V Catenacci Joseph Chao Kei Muro Salah Eddin Al-Batran Samuel J Klempner Zev A Wainberg Manish A Shah Sun Young Rha Atsushi Ohtsu Astra M Liepa Holly Knoderer Anindya Chatterjee Eric Van Cutsem Source Type: research
